China Brilliant Global Limited Stocks

HK$ 0.3Last Updated 13.04.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

HK$ 58.79M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 0.3
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

China Brilliant Global Limited, an investment holding company, engages in the research and development, design, wholesale, and retail of gold and jewelry, and related ancillary businesses in Hong Kong and the Peoples' Republic of China. The company operates through Gold and Jewellery Business, Lending Business, and Fintech Business segments. It is also involved in the banking activities, such as accepting deposits, granting credits, advising on credit financing, and arranging credit financing, as well as provision of money services; and money lending business. The company was formerly known as Prosten Health Holdings Limited and changed its name to China Brilliant Global Limited in May 2018. China Brilliant Global Limited was incorporated in 1989 and is headquartered in Sheung Wan, Hong Kong. China Brilliant Global Limited is a subsidiary of Brilliant Chapter Limited.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks